R&D News | pharmaphorum

News

MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.

News

AbbVie agrees a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will add an oral peptide for psoriasis to its pipeline.

News

Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.

News

An unexpected side effect has led Keros to halt dosing in two arms of its phase 2 trial of pulmonary arterial hypertension drug cibotercept.

News

Essential Pharma announces a €900m recapitalisation deal, while Noema Pharma, Angitia Biopharma, Citryll, and Veradermics also raise new cash.

News

Another clinical trial has found that SIGA Technologies' antiviral drug TPOXX (tecovirimat) is ineffective as a treatment for mpox.